Compare TSLX & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSLX | PGEN |
|---|---|---|
| Founded | 2010 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2014 | N/A |
| Metric | TSLX | PGEN |
|---|---|---|
| Price | $19.23 | $4.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $23.50 | $7.67 |
| AVG Volume (30 Days) | 745.1K | ★ 3.4M |
| Earning Date | 02-12-2026 | 03-18-2026 |
| Dividend Yield | ★ 10.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.81 | N/A |
| Revenue | ★ $449,055,000.00 | $6,309,000.00 |
| Revenue This Year | N/A | $342.78 |
| Revenue Next Year | N/A | $478.46 |
| P/E Ratio | $10.62 | ★ N/A |
| Revenue Growth | N/A | ★ 59.20 |
| 52 Week Low | $18.58 | $1.11 |
| 52 Week High | $25.17 | $5.23 |
| Indicator | TSLX | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 25.63 | 58.55 |
| Support Level | $19.63 | $4.41 |
| Resistance Level | $20.35 | $5.00 |
| Average True Range (ATR) | 0.59 | 0.38 |
| MACD | -0.21 | 0.02 |
| Stochastic Oscillator | 3.85 | 90.00 |
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.